A5055389581- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Phagocytosis and Immune Regulation
- Chronic Myeloid Leukemia Treatments
- PI3K/AKT/mTOR signaling in cancer
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Metabolism, Diabetes, and Cancer
- Lipid metabolism and disorders
- Histone Deacetylase Inhibitors Research
- Glycosylation and Glycoproteins Research
- Protein Degradation and Inhibitors
- Tryptophan and brain disorders
- Calcium signaling and nucleotide metabolism
- Childhood Cancer Survivors' Quality of Life
- Bipolar Disorder and Treatment
- RNA Interference and Gene Delivery
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Ubiquitin and proteasome pathways
- Cell death mechanisms and regulation
Azienda Ospedaliero-Universitaria di Modena
2023-2024
University of Modena and Reggio Emilia
2014-2023
The University of Texas MD Anderson Cancer Center
2013
Macrophages reside in tissues infiltrated by chronic lymphocytic leukemia B cells and the extent of infiltration is associated with adverse prognostic factors. We studied blood monocyte population flow cytometry whole-genome microarrays. A mixed lymphocyte reaction was performed to evaluate proliferation T contact monocytes from patients normal donors. Migration gene modulation cultured CLL were also evaluated. The absolute number increased compared controls (792±86 cells/μL versus 485±46...
// Stefania Fiorcari 1, * , Rossana Maffei Valentina Audrito 2 Silvia Martinelli 1 Elisa ten Hacken 3 Patrizia Zucchini Giulia Grisendi Leonardo Potenza Mario Luppi Jan A. Burger Deaglio Roberto Marasca Hematology Unit, Department of Medical and Surgical Sciences, University Modena Reggio Emilia, Modena, Italy Turin Human Genetics Foundation, Turin, Leukemia, The Texas MD Anderson Cancer Center, Houston, TX, USA These authors have contributed equally to this work Correspondence to: Marasca,...
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with increase in lymphocytosis, prior to inducing objective responses patients. This characteristic activity presumably due redistribution from tissues into blood, but underlying mechanisms are not fully understood. We therefore analyzed idelalisib effects on adhesion endothelial bone...
Infections represent a cause of morbidity and mortality in patients affected by chronic lymphocytic leukemia (CLL). Introduction new drugs CLL clinical practice has showed impressive efficacy, particular those targeting BTK. Among the consistent data, an increasing number reports describing occurrence unexpected opportunistic fungal infections been reported during treatment with ibrutinib first 6 months treatment. The reason underlying manifestations invasive treated is still under...
Sarcomas are frequent tumors in children and young adults that, despite a relative chemo-sensitivity, show high relapse rates with up to 80% of metastatic patients dying 5 years from diagnosis. The real ontogeny sarcomas is still debated evidences suggest they may derive precursors identified within mesenchymal stromal/stem cells (MSC) fractions. Recent studies on sarcoma microenvironment additionally indicated that MSC could take active part generation supportive stroma. Based this...
Lenalidomide is an immunomodulatory agent clinically active in chronic lymphocytic leukemia patients. The specific mechanism of action still undefined, but includes modulation the microenvironment. In patients, nurse-like cells differentiate from CD14+ mononuclear and protect apoptosis. Nurse-like resemble M2 macrophages with potent immunosuppressive functions. Here, we examined effect lenalidomide on monocyte/macrophage population We found that induces high actin polymerization monocytes...
The endothelin axis, comprising endothelins (ET-1, ET-2 and ET-3) their receptors (ETAR ETBR), has emerged as relevant player in tumor growth metastasis. Here, we investigated the involvement of ET-1/ETAR axis chronic lymphocytic leukemia (CLL). CLL cells expressed higher levels ET-1 ETA receptor compared to normal B cells. peptide stimulated phosphoinositide-3-kinase mitogen-activated protein kinase signaling pathways, improved survival promoted proliferation leukemic throughout ETAR...
Increasing evidence suggests a key role for angiopoietin-2 (ANGPT2) in influencing the aggressiveness of chronic lymphocytic leukemia (CLL). In presence vascular endothelial growth factor (VEGF), ANGPT2 causes vessel destabilization leading to neoangiogenesis. Accordingly, high expression levels and degree angiogenesis have consistently been associated with poor prognosis CLL; however, molecular mechanisms behind variability are still be discovered. Here, first time, we investigated DNA...
We investigated the cytotoxic interactions of romidepsin, a histone deacetylase inhibitor, and lenalidomide, an immunomodulatory agent, in T-cell lymphoma preclinical model. Hut-78 Karpas-299 cells were treated with romidepsin lenalidomide alone combination. The interaction between was evaluated by Chou–Talalay method, cell viability clonogenicity also evaluated. Apoptosis, reactive oxygen species (ROS) levels, cycle distribution determined flow cytometry. ER stress, caspase activation, AKT,...
Chronic lymphocytic leukemia (CLL) has experienced a clinical revolution-thanks to the discovery of crucial pathogenic mechanisms. CLL is still an incurable disease due intrinsic or acquired resistance leukemic clone. Venetoclax Bcl-2 inhibitor with marked activity in CLL, but emerging patterns are being described. We hypothesize that features cells may contribute drive mechanisms venetoclax. analyzed expression Interferon Regulatory Factor 4 (IRF4), Notch2, and Mcl-1 cohort patients....
Background Chronic lymphocytic leukemia B cells display prolonged survival in vivo, but when cultured vitro rapidly undergo spontaneous apoptosis. We hypothesize that interactions with endothelial infiltrated tissues and during recirculation may have a pathogenic role chronic leukemia.Design Methods evaluated apoptosis of leukemic after co-culture on monolayer human umbilical vein addition fludarabine antibodies block adhesion. Then, we compared microarray-based gene expression profiles...
Abstract Deletion on the long arm of chromosome 11 occurs in 5–20% chronic lymphocytic leukaemia (CLL) patients. We analysed clinical–biological characteristics 131 CLL patients carrying 11q deletion documented before therapy ( de novo deleted CLL). De were characterized by high frequencies unmutated immunoglobulin variable heavy genes, multiple fluorescence situ hybridization aberrations and lymph node involvement. Factors significantly associated with shorter time to first treatment (TTFT)...
In recent years, the introduction of new drugs targeting Bruton's tyrosine kinase (BTK) has allowed dramatic improvement in prognosis patients with chronic lymphocytic leukemia (CLL) and other B-cell neoplasms. Although these small molecules were initially considered less immunosuppressive than chemoimmunotherapy, an increasing number reports have described occurrence unexpected opportunistic fungal infections, particular invasive aspergillosis (IA). BTK represents a crucial molecule several...
The indoleamine 2,3-dioxygenase 1 (IDO1) metabolic circuitry, comprising the first tryptophan (Trp) catabolite L-kynurenine (Kyn) and aryl hydrocarbon receptor (AHR), has emerged as a mechanism of cancer immune evasion. Here, we investigated functional role IDO1/Kyn/AHR axis in chronic lymphocytic leukemia (CLL). Our data show that CLL cells expressed an active form IDO1 enzyme microenvironmental stimuli can positively modulate its expression. Interferon (IFN)-γ induces expression through...